Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0113-6861 · 1 trial · 2 indications
hours
| Arm | Type | Description |
|---|---|---|
| Study compound 1 | EXPERIMENTAL | Up to 6 volunteers will receive one dose of study compound 1 |
| Study compound 2 | EXPERIMENTAL | Up to 6 volunteers will receive one dose of study compound 2 |
| Study compound 3 | EXPERIMENTAL | Up to 6 volunteers will receive one dose of study compound 3 |
| Name | Type | Description |
|---|---|---|
| NNC0113-6861 | DRUG | Study compound 1 - Each participant will receive a single intravenous (i.v) dose of \[14C\]-NNC0113-6861 |
| NNC0113-6860 | DRUG | Study compound 2 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6860 |
| NNC0113-6891 | DRUG | Study compound 3 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6891 |
Inclusion Criteria: * Healthy subject. * Sex : Male. * Age 18 to 54 years, inclusive, at the time of signing informed consent. * Body mass index (BMI) 18.0 to 30.0 kg/m\^2, inclusive, at the time of signing informed consent . Exclusion Criteria: * Known or suspected hypersensitivity to study prod...
Top 16 of 30 competitors
NNC0113-6861 is an investigational small molecule being developed by Novo Nordisk for the treatment of type 2 diabetes. It is in Phase 1 clinical development and has been studied in a single completed trial involving 18 participants. It is not an approved medicine.
NNC0113-6861 is being developed as a potential treatment for type 2 diabetes. It has been evaluated in a Phase 1 study that enrolled healthy volunteers and people with type 2 diabetes. It remains investigational and is not available as a prescribed therapy.
NNC0113-6861 is developed by Novo Nordisk A/S, the Danish pharmaceutical company whose shares trade under the ticker NVO. Novo Nordisk is the sponsor of the clinical program studying this small molecule in type 2 diabetes.
NNC0113-6861 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently listed as active. The compound is investigational and has not been approved for any indication.
NNC0113-6861 has been studied in one completed Phase 1 trial, NCT04676906, titled A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds. It enrolled 18 male participants aged 18 years and older in the Netherlands and included healthy volunteers and people with type 2 diabetes.